Skip to main content

Advertisement

Figure 2 | BMC Cancer

Figure 2

From: A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

Figure 2

The 180-gene GEPR to EGFR-targeted therapy stratifies a patient population demonstrating longer progression-free survival in metastatic CRC patients treated with cetuximab. The data from Khambata-Ford et al were classified using our predictive model and matched to PFS. The scatter plots (left) depict the individual data points and median PFS for each group. The Kaplan-Meier survival curves (right) depict PFS between the 'sensitive' (green) and 'resistant' (red) groups. A: KRAS-wildtype patients; B: all patients; and C: KRAS-mutant patients.

Back to article page